| First Author | He Y | Year | 2021 |
| Journal | Cell Metab | Volume | 33 |
| Issue | 5 | Pages | 988-1000.e7 |
| PubMed ID | 33761313 | Mgi Jnum | J:305909 |
| Mgi Id | MGI:6707890 | Doi | 10.1016/j.cmet.2021.03.002 |
| Citation | He Y, et al. (2021) Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity. Cell Metab 33(5):988-1000.e7 |
| abstractText | Recent studies in both mice and humans have suggested that gut microbiota could modulate tumor responsiveness to chemo- or immunotherapies. However, the underlying mechanism is not clear yet. Here, we found that gut microbial metabolites, especially butyrate, could promote the efficacy of oxaliplatin by modulating CD8(+) T cell function in the tumor microenvironment. Butyrate treatment directly boosted the antitumor cytotoxic CD8(+) T cell responses both in vitro and in vivo in an ID2-dependent manner by promoting the IL-12 signaling pathway. In humans, the oxaliplatin responder cancer patients exhibited a higher amount of serum butyrate than did non-responders, which could also increase ID2 expression and function of human CD8(+) T cells. Together, our findings suggest that the gut microbial metabolite butyrate could promote antitumor therapeutic efficacy through the ID2-dependent regulation of CD8(+) T cell immunity, indicating that gut microbial metabolites could be effective as a part of cancer therapy. |
